MASHINIi

Insight Molecular Diagnostics Inc..

IMDX.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products

Insight Molecular Diagnostics Inc. (IMDX.US) is a biotechnology company focused on developing and commercializing molecular diagnostic tests. These tests are designed to detect infectious diseases and other medical conditions by analyzing patient samples at the molecular level. The company's primary...Show More

Ethical Profile

Mixed.

Insight Molecular Diagnostics Inc. (IMDX.US) presents a mixed ethical profile. The company demonstrates a commitment to health innovation, with its VitaGraft Kidney test showing favorable results in a New England Journal of Medicine study, potentially improving patient outcomes. IMDX also invested $2.5 million in R&D in Q2 2024, a 6% increase. However, critics point to concerns that the company's diagnostic products may not be accessible to all populations due to pricing, and there is no mention of specific health equity programs. Reports suggest insufficient public information regarding IMDX's practices in areas like fair pay, ethical sourcing, environmental impact, or data security.

Value Scores

Better Health for All20
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect0
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business0
-100100
Kind to Animals0
-100100
No War, No Weapons0
-100100
Planet-Friendly Business-40
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech0
-100100
Zero Waste & Sustainable Products0
-100100

Better Health for All

20

The company's core business involves molecular diagnostic tests for critical conditions such as kidney transplant rejection and brain tumors.

1
These products, including GraftAssureIQ, VitaGraft Kidney, and liquid biopsy for brain tumors, provide substantial health benefits by enabling early detection, monitoring, and guiding treatment, with no evidence of negative health outcomes.
2
The company's R&D expense for Q2 2024 was $2.5 million, which represents approximately 53% of its Q2 2024 operating expenses of $4.7 million.
3
However, the rubric's KPI for health innovation investment is based on the share of R&D budget allocated to health improvement, not as a percentage of operating expenses. The company's R&D expense of $2.5 million is not provided as a percentage of its total R&D budget or capital allocation, making it difficult to precisely map to the rubric's tiers. Given the company's focus on diagnostics, it is reasonable to assume that a significant portion of its R&D is for health improvement, but without a specific percentage, a conservative score is applied. There is no evidence of revenue from products with negative health outcomes.
4

Fair Money & Economic Opportunity

0

No evidence available to assess Insight Molecular Diagnostics Inc. on Fair Money & Economic Opportunity.

Fair Pay & Worker Respect

0

No evidence available to assess Insight Molecular Diagnostics Inc. on Fair Pay & Worker Respect.

Fair Trade & Ethical Sourcing

0

No specific, quantitative evidence regarding IMDX.US's fair trade and ethical sourcing practices, such as fair-trade certification share, audit frequency, forced/child labor incidents, traceability coverage, remediation speed, ethical clause coverage, materials risk index, or supplier diversity spend, was found in the provided articles.

1

Honest & Fair Business

0

No evidence available to assess Insight Molecular Diagnostics Inc. on Honest & Fair Business.

Kind to Animals

0

No evidence available to assess Insight Molecular Diagnostics Inc. on Kind to Animals.

No War, No Weapons

0

No evidence available to assess Insight Molecular Diagnostics Inc. on No War, No Weapons.

Planet-Friendly Business

-40

IMDX.US has committed to the UN-backed 'Race to Zero' initiative, pledging net-zero greenhouse gas emissions by 2050.

1
The company focuses on resource efficiency, maximizing productivity, and eliminating waste.
2
Specific strategies include using alternative sample types, lyophilization of reagents to eliminate cold-chain transport, and reducing assay steps and materials.
3
The company also uses animal-free reagents to reduce environmental impact.
4

Respect for Cultures & Communities

0

No specific data or information regarding IMDX.US's performance on 'Respect for Cultures & Communities' was found in the provided articles.

1
Both articles explicitly state that they do not contain any relevant metrics or data for the requested criteria.
2

Safe & Smart Tech

0

No specific, concrete evidence regarding IMDX.US's performance on any of the 'Safe & Smart Tech' KPIs was found in the provided articles. The articles discuss general industry trends, recommendations, or provide information about other companies, but do not offer specific data points for Insight Molecular Diagnostics Inc. (IMDX.US).

Zero Waste & Sustainable Products

0

No specific, quantitative data for IMDX.US regarding waste management, product sustainability, or circular economy practices was found in the provided articles. Several articles discussed sustainability efforts of other companies (QIAGEN, Illumina, Meridian Bioscience, Insight.com) or general industry strategies, but explicitly stated that the information did not pertain to IMDX.US. One article about IMDX.US focused on a name change and headquarters relocation, without any details on its waste or product sustainability performance.

1

Own Insight Molecular Diagnostics Inc.?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.